Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
== Epidemiology == The allergic diseases—hay fever and asthma—have increased in the Western world over the past 2–3 decades. Increases in allergic asthma and other atopic disorders in industrialized nations, it is estimated, began in the 1960s and 1970s, with further increases occurring during the 1980s and 1990s, although some suggest that a steady rise in sensitization has been occurring since the 1920s. The number of new cases per year of atopy in developing countries has, in general, remained much lower.
S-Arrestin is a protein found in mice that binds to rhodopsin to stop its activity, preventing further signaling. S-arrestin binds to G protein-coupled receptors (GPCRs), like rhodopsin, following receptor activation and phosphorylation by G protein-coupled receptor kinases (GRKs). Rhodopsin is found in rod cells of the retina, essential for vision. It detects light and initiates a signaling cascade called phototransduction. However, excessive activation can be harmful, so it must be carefully regulated. The phosphorylation of the receptor's intracellular loops and C-terminal tail creates a high-affinity binding site for S-arrestin. S-arrestin then sterically hinders further G protein coupling, effectively desensitizing the receptor and directing it towards alternative signaling pathways or internalization via clathrin-mediated endocytosis.
Jonathan E. Mangum is an Australian biomedical scientist, entrepreneur, and executive known for his contributions to translational proteomics and the development of diagnostic technologies in oral health. He is a co-founder of Incisive Technologies and the scientific lead behind BlueCheck, a diagnostic tool for early detection of dental caries, which received FDA clearance in 2023. Mangum earned his Bachelor and Master of Science degrees in Biochemistry from the University of Otago in New Zealand (1995–2000). He completed a PhD in Biomedical Sciences at the University of Melbourne in 2013. He also holds a Graduate Certificate in Commercialisation from Melbourne Business School.
Naturally occurring zirconium (40Zr) is composed of four stable isotopes (one, 94Zr, may in the future be found radioactive), and one very long-lived radioisotope (96Zr), a primordial nuclide that decays via double beta decay with an observed partial half-life of 2.34 × 1019 years; it can also undergo single beta decay, with a partial half-life of [2.27+0.53−0.36 (stat) ± 0.27 (syst)] × 1020 years. The second most stable radioisotope is 93Zr, which has a half-life of 1.61 million years. Thirty other radioisotopes have been observed from 77Zr to 114Zr; all have half-lives less than a day except for 95Zr (64.032 days), 88Zr (83.4 days), and 89Zr (78.36 hours). The most stable of the isomeric states is just 4.16 minutes for 89mZr. Radioactive isotopes above the theoretically stable mass numbers 90–92 decay by electron emission resulting in niobium isotopes, whereas those below by positron emission or electron capture, resulting in yttrium isotopes.
== Side effects == Adverse events include hypoglycemia, pruritus (itch), nasopharyngitis, headache, and upper respiratory tract infection. It may also cause joint pain that can be severe and disabling. Like other DDP-4 inhibitors, alogliptin is weight-neutral. A 2014 letter to the editor claimed alogliptin is not associated with increased risk of cardiovascular events. In April 2016, the U.S. Food and Drug Administration (FDA) added a warning about increased risk of heart failure.
Sources: en.wikipedia.org
====== Fatty acid ethoxylates ====== Fatty acid ethoxylates are a class of very versatile surfactants, which combine in a single molecule the characteristic of a weakly anionic, pH-responsive head group with the presence of stabilizing and temperature responsive ethyleneoxide units.
Na + KCl → NaCl + K, became the dominant method in the 1950s. The production of sodium–potassium alloys is accomplished by changing the reaction time and the amount of sodium used in the reaction. The Griesheimer process employing the reaction of potassium fluoride with calcium carbide was also used to produce potassium.
== Sources == Over the years, numerous sources have been experimented. Pirie and Telek described LPC production using a combination of pulping and heat coagulation. Leaves are typically sourced from shrubs or agricultural wastes given their ease of access and relative abundance. Trees are generally considered a poor source of leaf mass for the production of LPC given restrictions on the ease of access. Fallen leaves/leaf litter have negligible protein-content and are of no extractive value. Plants belonging to the Fabaceae family such as clover, peas and legumes have also been prime candidates for LPC production. While most plants have a mean leaf protein content of 4 to 6% w/v. Fabaceae plants tend to have nearly double that value at 8 to 10% v/w, depending on the protein estimation method employed. Other non-traditional sources include agricultural wastes such as pea (Pisum sativum) pods, cauliflower (Brassica oleracea) leaves, as well as invasive plants such as gorse (Ulex europeaus), broom (Cytisus scoparius), and bracken (Pteridium aquilinum).
The vascular network within the islets resembles a glomeruli-like structure, consisting of highly fenestrated endothelial cells positioned closely to each endocrine cell. Consequently, the oxygen tension within pancreatic islets is significantly higher than that in the surrounding exocrine tissue.
Sources: en.wikipedia.org
== External links == Cofactors lecture Archived 2016-10-05 at the Wayback Machine (Powerpoint file) Enzyme+cofactors at the U.S. National Library of Medicine Medical Subject Headings (MeSH) The CoFactor Database
Carboxypeptidases hydrolyze peptides at the first amide or polypeptide bond on the C-terminal end of the chain. Carboxypeptidases act by replacing the substrate water with a carbonyl (C=O) group. The carboxypeptidase A hydrolysis reaction has two mechanistic hypotheses, via a nucleophilic water and via an anhydride. In the first proposed mechanism, a promoted-water pathway is favoured as Glu270 deprotonates the nucleophilic water. The Zn2+ ion, along with positively charged residues, decreases the pKa of the bound water to approximately 7. Glu 270 has a dual role in this mechanism as it acts as a base to allow for the attack at the amide carbonyl group during nucleophilic addition. It acts as an acid during elimination when the water proton is transferred to the leaving nitrogen group. The oxygen on the amide carbonyl group does not coordinate to the Zn2+ until the addition of the water. The deprotonation of the Zn2+ coordinated water by Glu 270 provides an activated hydroxide nucleophile which attacks the amide carbonyl group in the peptide bond in a nucleophilic addition. The negatively charged intermediates that are formed during hydrolysis are stabilized by the Zn2+ ion. The interaction between the carbonyl group and the neighbouring arginine, Arg 217, also stabilizes the negatively charged intermediates. The zinc-bound hydroxide interacts with the amide with the electrostatic stabilization of the transition state provided by the Zn2+ ion and the neighbouring arginine.
==== Spanish colonial America ==== In Jamaica and elsewhere in the Caribbean area, the Spanish enslaved many of the Taino natives. Some of them escaped, and some hurled themselves and their children off of cliffs to avoid enslavement, but most died from European diseases and overwork. The practice began under Christopher Columbus, who was looking for gold to finance his future expeditions, and was continued by the other conquistadors who followed in his wake. In 1519, Hernán Cortés brought the first modern slave to Mexico. In the mid-16th century, the Spanish New Laws, prohibited slavery of the indigenous people, including the Aztecs. A labour shortage resulted. This led to the African slaves being imported, as they were not susceptible to smallpox. In exchange, many Africans were afforded the opportunity to buy their freedom, while eventually others were granted their freedom by their masters. Spain practically did not trade in slaves until 1810 after the rebellions and independence of its American territories or viceroyalties. After the Napoleonic invasions, Spain had lost its industry and its American territories, except in Cuba and Puerto Rico, where the African slave trade to Cuba began on a massive scale from 1810 onwards. It was started by French planters exiled from the French lost colony Saint Domingue (Haiti) who settled in the eastern part of Cuba. In 1789, the Spanish Crown led an effort to reform slavery, as the demand for slave labour in Cuba was growing.
== Coups d'état == "...Thailand has experienced more coups d'état than any other country in contemporary history." according to The Washington Post. Since 1932, Thailand has had seven coup attempts and 12 successful coups (as of 2015).
== Public policy activities == • Coordination of the development of the health plans of Debrecen (2002, 2008) and Budapest (2012–2014) • Coordination of the strategic planning of the National Public Health Programme (2018–2030; 2023–2033) • Organisation and operation of the General Practitioners’ Morbidity Data Collection Programme (1998–2017) • Coordination of the establishment of the North‑East Hungarian Health Observatory (2005) • Coordination of the primary care development model programme based on general practitioners’ clusters, supported by the Hungarian Government and the Swiss Contribution (2012–2016), integrating primary care and public health services. She has led more than forty national research and educational development projects, including the major project “Improving the competitiveness of the Hungarian economy through identifying target groups and content of public health interventions to improve population health” (2016–2021), which resulted in 123 international publications and 32 completed PhD degrees. Her research groups have participated in more than twenty international projects, often under her leadership.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.